3Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease:a spectrum of clinical and pathological severity [ J ]. Gastroenterology, 1999, 116:1 413-419.
4Ekstedt M, Franzen LE, Mathiesen UL, Long-term follow-wp of patients with NAFLD and elevated liver enzymes [J]. Hepatology, 2006, 44: 865-873.
5Ioannou GN, Weiss NS, Boyko F J, et al. Elevated serum alanine aminotrasferase activity and calculated risk of coronary heart disease in the United Stales [J]. Hepatology, 2006, 43: I 145-151.
6Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease [ J ]. Hepatology, 2005, 42: 473-478.
7Targher G, Bertolini L, Padovani R, et al. Relations between cared wall thickness and liver histology in subjects with nonalcoholic fatty liver disease [J]. Diab Care, 2006, 29: 1325-330.
8O'Leary DH, Polak JF, Kronmal BA, et al. Distribution and correlates of sonographically detected carotid artery disease in the cardiovascular health study [J]. Stroke, 1992, 23:1 752-760.
9Schindhelm RK, Diamant M, Bakker SJ, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in nonmotriglyceridaemie subjects with type 2 diabetes mellitus [ J ]. Eur J Clin Intest,2005,215:369-374.
10Schwimmer JB, Deutsch R, Behling C, et al. Fatty liver as a determinant of atherosclerosia [J]. Hepatology, 2005, 42: 610A.
